Browsing: Genitourinary

Top Line: Over a short period of time in, we’ve seen a lot of exciting breakthroughs in the management of…

A retrospective look at 449 patients receiving enfortumab vedotin for urothelial cancer reports over one-quarter (n=127) developed associated cutaneous reactions–most…

This multi-institutional retrospective analysis compared standard-dose bladder radiotherapy (55 Gy/20 or 64 Gy/32) with a simultaneous integrated boost (up to…

Top Line: Cisplatin has been the perioperative standard for eligible patients with muscle-invasive bladder cancer for over two decades. The…

Top Line: Could induction dual-checkpoint blockade expand bladder preservation beyond the “ideal” trimodality candidate?The Study: The phase II single-arm INDIBLADE…

Top Line: The FASTRACK trials represent landmark prospective evidence establishing SABR as a safe and effective non-invasive treatment for RCC…

Top Line: Does adjuvant radiation improve disease control in patients with high risk bladder cancer?The Study: In few disease sites…

Renal cell carcinoma includes clear cell (75–80%) and heterogeneous non–clear cell subtypes. While surgery remains the standard treatment for all…

Top Line: Is there an effective adjunct systemic therapy regimen for cisplatin-ineligible patients choosing definitive surgery for muscle-invasive bladder cancer…

Top Line: Determining the ideal fractionation scheme for definitive stereotactic ablative radiation (SABR) for renal cell carcinoma (RCC) depends largely…